Abatacept

阿巴西普

Report date: 2026/01/12 09:28:14
First In Class

Base Information

Drug NameAbatacept
Drug Alias NameOrencia IV阿他西普阿巴西普hCTLA4-Ig-Bristol-Myers-Squibb阿贝西普 +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 80 modulatorsCluster of differentiation 86 modulators
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsRejection of renal transplantationKostmann SyndromeCoronavirus Disease 2019 (COVID-19) +[67] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryUnited States
Original Approved Date2005/12/23
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdDuke University +[10] 
Inactive CompaniesUtah State UniversityUniversity Medical Center GroningenOregon Health And Science University +[20] 
Active IndicationsRejection of renal transplantationCommon Variable ImmunodeficiencyGraft vs Host Disease +[19] 
Inactive IndicationsKostmann SyndromeCoronavirus Disease 2019 (COVID-19)Allergic asthma +[48] 

Other Information

ATC CodeL04AA24
Related LinksWikipediaDrugBankKEGG